Cellectar Biosciences Signals Pivotal Turn in Earnings Call

Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Cellectar Biosciences (CLRB) Reports Positive Phase IIb Results and Plans FDA Filing

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Cellectar plans phase III start in late Q4 2026 as it outlines potential WM approval in the second half of 2027

Cellectar Biosciences Reports Positive Phase 2b Data for Iopofosine I 131 in Waldenström Macroglobulinemia and Secures $140M Financing for Phase 3 Trial and FDA Filing

Is Cellectar Biosciences (CLRB) Attractively Valued After Q1 202

Cellectar Biosciences Releases Q1 2026 Financial Results

Cellectar Biosciences Q1 2026: Loss Narrows 29.6% to -$1.33/Share

CLRB: Strong clinical results and $140M financing drive late-stage execution and regulatory momentum

Cellectar (CLRB) Secures $140 Million Financing for Regulatory M

Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call

CLRB: Strong efficacy in r/r WM and robust financing position clinical programs for key milestones

Cellectar Biosciences reports Q1 2026 net loss of $5.65M; cash $8.3M before $31M financing

Cellectar Biosciences (CLRB) posts Q1 2026 loss and secures up to $140M

Press Release: Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Cellectar Biosciences, Inc. Q1 2026: Net loss $(5.65M), EPS $(1.33) — 10-Q Summary

Cellectar Biosciences (NASDAQ: CLRB) posts Q1 loss and flags going-concern risk